4D Molecular Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FDMT research report →
Range $20 – $37
Price Chart
About the company
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders).
- CEO
- David H. Kirn
- IPO
- 2020
- Employees
- 196
- HQ
- EmeryVille, CA, US
Get TickerSpark's AI analysis on FDMT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $664.69M
- P/E
- -4.67
- PEG
- -0.32
- P/S
- 7.22
- P/B
- 2.19
- EV/EBITDA
- -3.43
- Div Yield
- 0.00%
- Gross Margin
- 42.00%
- Op Margin
- -214.24%
- Net Margin
- -194.74%
- ROE
- -41.33%
- ROIC
- -43.77%
Latest fiscal year · YoY change
- Revenue
- $85.21M+230194.6%
- Gross Profit
- $77.58M+154.9%
- Op Income
- $-159,547,000
- Net Income
- $-140,109,000+12.9%
- EPS
- $-2.42+18.8%
- OCF Growth
- +18.9%
- FCF Growth
- +21.2%
- 52W High
- $16.93
- 52W Low
- $6.96
- 50D MA
- $13.46
- 200D MA
- $10.45
- Beta
- 2.73
- RSI (14)
- 37
- Avg Volume
- 915.93K
No earnings-call transcripts are available for FDMT yet.
- Free Float
- 74.6%
- Shares Outstanding
- 52.28M
- Float Shares
- 39.01M
of shares held by institutions
166 13F filers
Buy/sell ratio 0.20. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Jupiter Topco LLC | 5.75M | ▲ 5.75M |
| Janus Henderson Group Ltd. | 5.25M | ▲ 611.28K |
| Ra Capital Management, L.P. | 5.05M | 0 |
| Blackrock, Inc. | 4.55M | ▲ 400.76K |
| Goldman Sachs Group Inc | 4.26M | ▲ 53.23K |
| Novo Holdings A/S | 3.25M | ▼ 401.56K |
| Vanguard Group Inc | 3.09M | ▲ 518.40K |
| State Street Corp | 2.91M | ▲ 203.23K |
| Bvf Inc/Il | 2.88M | 0 |
| T. Rowe Price Investment Management, Inc. | 2.51M | ▲ 2.51M |
| Adage Capital Partners Gp, L.L.C. | 2.25M | ▲ 644.05K |
| Trails Edge Capital Partners, LP | 2.23M | ▲ 925.00K |
Held by 186 ETFs
Biggest fund positions in FDMT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 16, 26 | Bizily Scott | other | 1,635 |
| Sep 16, 26 | Bizily Scott | other | 1,635 |
| Sep 16, 26 | Bizily Scott | sell | 1,635 |
| Sep 14, 26 | Kirn David | sell | 58,333 |
| Sep 1, 26 | Bizily Scott | other | 584 |
| Sep 1, 26 | Bizily Scott | sell | 584 |
| Sep 1, 26 | Bizily Scott | other | 584 |
| Aug 19, 26 | Kirn David | other | 50,000 |
| Aug 19, 26 | Kirn David | sell | 43,149 |
| Aug 19, 26 | Kirn David | sell | 25,927 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our FDMT coverage
Recent articles, reports, and earnings notes.
No research on FDMT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FDMT report →4DMT to Host Investor Day on October 21, 2026
globenewswire.com · Oct 5
4D Molecular: Reiterate 'Buy' With Wet AMD 4D-150 Program On Track And Phase 3 DME Trial Underway
seekingalpha.com · Sep 29
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
globenewswire.com · Sep 28
Scott Bizily Sells 1,635 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock
defenseworld.net · Sep 24
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $28.56 Average PT from Brokerages
defenseworld.net · Sep 21
4D Molecular Therapeutics, Inc. (FDMT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
seekingalpha.com · Sep 17
4D Molecular Therapeutics, Inc. (FDMT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com · Sep 14
4DMT Announces New Employment Inducement Grants
globenewswire.com · Sep 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.